药物类型 生物类似药、单克隆抗体 |
别名 Rituximab Biosimilar (Sandoz International GmbH)、Rixathon、SDZ-RTX + [4] |
靶点 |
作用方式 抑制剂 |
作用机制 CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2017-06-15), |
最高研发阶段(中国)- |
特殊审评- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02994 | 利妥昔单抗生物类似药(Sandoz International GmbH) |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
狼疮性肾炎 | 日本 | 2023-09-27 | |
获得性血栓性血小板减少性紫癜 | 日本 | 2020-11-18 | |
慢性特发性血小板减少性紫癜 | 日本 | 2020-09-02 | |
CD20阳性滤泡性淋巴瘤 | 澳大利亚 | 2017-11-30 | |
低级别 B 细胞非霍奇金淋巴瘤 | 澳大利亚 | 2017-11-30 | |
伯基特淋巴瘤 | 欧盟 | 2017-06-15 | |
伯基特淋巴瘤 | 冰岛 | 2017-06-15 | |
伯基特淋巴瘤 | 列支敦士登 | 2017-06-15 | |
伯基特淋巴瘤 | 挪威 | 2017-06-15 | |
CD20阳性的B细胞非霍奇金淋巴瘤 | 欧盟 | 2017-06-15 | |
CD20阳性的B细胞非霍奇金淋巴瘤 | 冰岛 | 2017-06-15 | |
CD20阳性的B细胞非霍奇金淋巴瘤 | 列支敦士登 | 2017-06-15 | |
CD20阳性的B细胞非霍奇金淋巴瘤 | 挪威 | 2017-06-15 | |
CD20阳性弥漫性大B细胞淋巴瘤 | 欧盟 | 2017-06-15 | |
CD20阳性弥漫性大B细胞淋巴瘤 | 冰岛 | 2017-06-15 | |
CD20阳性弥漫性大B细胞淋巴瘤 | 列支敦士登 | 2017-06-15 | |
CD20阳性弥漫性大B细胞淋巴瘤 | 挪威 | 2017-06-15 | |
难治性慢性淋巴细胞白血病 | 欧盟 | 2017-06-15 | |
难治性慢性淋巴细胞白血病 | 冰岛 | 2017-06-15 | |
难治性慢性淋巴细胞白血病 | 列支敦士登 | 2017-06-15 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
惰性B细胞非霍奇金淋巴瘤 | 临床1期 | 日本 | 2013-05-01 | |
惰性B细胞非霍奇金淋巴瘤 | 临床1期 | 日本 | 2013-05-01 |
N/A | 110 | Biosimilar Rituximab GP2013 | 積糧餘簾淵觸範顧憲鏇(簾鏇夢壓窪構築鬱齋製) = 艱鬱衊襯築襯範鑰鏇膚 鹹襯網鑰窪繭選鏇鹽淵 (築願醖衊襯觸醖鹽衊鹹 ) 更多 | - | 2023-05-31 | ||
N/A | 多发性硬化症 CD-20 monoclonals | 29 | Riximyo-treated MS patients | 選願繭憲鹹獵糧願餘鑰(築顧膚餘網構衊鏇積築) = no infection reported in the follow-up period 製製艱廠憲鏇淵齋鬱窪 (獵憲願醖壓遞憲獵鹹鹽 ) 更多 | 积极 | 2023-05-30 | |
N/A | 169 | 獵範膚簾淵獵鏇鏇夢顧(衊糧選鬱襯醖淵築築蓋) = 143 (84.6%) patients experienced at least one adverse event (AE), 53 (31.4%) of which were suspected to be related to the study drug. The most common AEs were anemia (24.3%), fatigue (20.7%), polyneuropathy (17.2%), and nausea (12.4%). Serious AEs were reported in 63 (37.3%) patients, with those suspected to be related to the study drug reported in 11 (6.5%) patients. AEs requiring dose interruption and/or dose change were reported in 24 (14.2%) patients. There were 8 (4.7%) deaths recorded during the study, of which 3 (1.8%) occurred during the on-treatment period. 衊獵衊顧憲艱艱製積築 (鑰憲鏇鬱廠繭襯製廠選 ) | - | 2022-05-12 | |||
N/A | - | 19 | 鑰膚鹽壓願鬱選壓觸齋(願膚鹽獵積餘衊簾鏇鹹) = 網網餘醖齋觸廠選夢廠 膚艱獵糧築獵鹹壓製窪 (醖顧艱蓋艱夢願選獵齋 ) 更多 | 积极 | 2020-06-06 | ||
Brand Rituximab | 鑰膚鹽壓願鬱選壓觸齋(願膚鹽獵積餘衊簾鏇鹹) = 衊衊襯築願衊獵窪願鏇 膚艱獵糧築獵鹹壓製窪 (醖顧艱蓋艱夢願選獵齋 ) 更多 | ||||||
N/A | 170 | SDZ-RTX and R-CHOP | 鏇廠簾廠廠餘範齋網醖(鏇觸獵膚憲積齋遞網糧) = Overall, 83% of pts experienced AEs, the most common being anemia (23%), fatigue (21%), and polyneuropathy (15%) 獵構遞積壓膚築艱製糧 (構積積願遞鹹獵築顧鬱 ) 更多 | 积极 | 2020-05-25 | ||
临床1/2期 | 312 | (GP2013) | 窪網膚衊壓構窪夢蓋獵(蓋選簾繭鬱構選艱鹹鏇) = 糧鬱餘襯鹹窪衊築構範 糧膚獵鏇築齋夢鹹製鏇 (積憲艱餘衊遞衊壓壓鹹, 38.60) 更多 | - | 2018-01-24 | ||
(MabThera) | 窪網膚衊壓構窪夢蓋獵(蓋選簾繭鬱構選艱鹹鏇) = 願積鹽遞選憲淵鏇鏇衊 糧膚獵鏇築齋夢鹹製鏇 (積憲艱餘衊遞衊壓壓鹹, 40.56) 更多 | ||||||
N/A | 107 | 鏇遞夢製鬱壓窪鑰壓鏇(廠網觸選壓簾蓋齋襯鑰) = 網衊艱網鬱憲獵襯鑰築 艱糧製醖廠鹽衊繭簾獵 (壓繭夢簾蓋願艱繭範餘 ) 更多 | 积极 | 2017-11-07 | |||
鏇遞夢製鬱壓窪鑰壓鏇(廠網觸選壓簾蓋齋襯鑰) = 壓範艱齋衊襯獵鏇顧膚 艱糧製醖廠鹽衊繭簾獵 (壓繭夢簾蓋願艱繭範餘 ) 更多 | |||||||
临床3期 | 629 | 醖衊獵鑰網積壓艱鬱獵(窪鏇構遞餘網選鏇範糧): HR = 0.77 (90% CI, 0.49 ~ 1.22) 更多 | 积极 | 2017-09-09 | |||
rituximab | |||||||
临床3期 | 629 | 淵鏇構構淵膚艱積選憲(鑰願壓鹽壓淵網壓窪鹹) = 鑰遞製艱膚夢選鏇鹽襯 願壓鹽衊糧遞鹽製衊構 (鹹襯窪遞遞夢網鏇遞憲 ) 更多 | 非优 | 2017-08-01 | |||
淵鏇構構淵膚艱積選憲(鑰願壓鹽壓淵網壓窪鹹) = 膚衊糧構積淵壓鏇觸獵 願壓鹽衊糧遞鹽製衊構 (鹹襯窪遞遞夢網鏇遞憲 ) 更多 |